Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib

Autor: Van 'T Veer, Laura, Ashworth, Alan, Daemen, A, Wolf, DM, Korkola, JE, Griffith, OL, Frankum, JR, Brough, R, Jakkula, LR, Wang, NJ, Natrajan, R, Reis-Filho, JS

Publikováno v: Van 'T Veer, Laura; Ashworth, Alan; Daemen, A; Wolf, DM; Korkola, JE; Griffith, OL; et al.(2012). Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/3b99265r

Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in DNA repair. PARP inhibitors can act as chemosensitizers, or operate on the principle of synthetic lethality when used as single agent. Clinical trials have shown drugs in this class to be pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::0568eda800d87a1f174ad5219d818921
http://www.escholarship.org/uc/item/3b99265r

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Erratum to: Modeling precision treatment of breast cancer.

Autor: Daemen A; Department of Cancer & DNA Damage Responses, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA. daemena@gene.com.; Laboratory Medicine, University of California San Francisco, San Francisco, CA, 94115, USA. daemena@gene.com.; Present address: Department of Bioinformatics & Computational Biology, Genentech Inc, 1 DNA Way, South San Francisco, CA, 94080, USA. daemena@gene.com., Griffith OL; Department of Cancer & DNA Damage Responses, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA. ogriffit@genome.wustl.edu.; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR, 97239, USA. ogriffit@genome.wustl.edu.; The Genome Institute, Washington University School of Medicine, St Louis, MO, 63105, USA. ogriffit@genome.wustl.edu., Heiser LM; Department of Cancer & DNA Damage Responses, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA. heiserl@ohsu.edu.; Department of Biomedical Engineering, Center for Spatial Systems Biomedicine, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, 97239, USA. heiserl@ohsu.edu., Wang NJ; Department of Cancer & DNA Damage Responses, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA. wangnic@ohsu.edu.; Department of Biomedical Engineering, Center for Spatial Systems Biomedicine, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, 97239, USA. wangnic@ohsu.edu., Enache OM; Department of Cancer & DNA Damage Responses, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA. oenache@berkeley.edu., Sanborn Z; Five3 genomics, 101 Cooper St, Santa Cruz, CA, 95060, USA. zack@five3genomics.com., Pepin F; Department of Cancer & DNA Damage Responses, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA. francois.pepin@sequenta.com.; Present address: Sequenta Inc, South San Francisco, CA, 94080, USA. francois.pepin@sequenta.com., Durinck S; Department of Cancer & DNA Damage Responses, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA. sdurinck@gmail.com., Korkola JE; Department of Cancer & DNA Damage Responses, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA. korkola@ohsu.edu.; Department of Biomedical Engineering, Center for Spatial Systems Biomedicine, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, 97239, USA. korkola@ohsu.edu., Griffith M; The Genome Institute, Washington University School of Medicine, St Louis, MO, 63105, USA. mgriffit@genome.wustl.edu., Hur JS; Samsung Electronics Headquarters, Seocho-gu, Seoul, 137-857, Korea. joe.hur@samsung.com., Huh N; Emerging Technology Research Center, Samsung Advanced Institute of Technology, Kyunggi-do, 446-712, Korea. namhuh@samsung.com., Chung J; Emerging Technology Research Center, Samsung Advanced Institute of Technology, Kyunggi-do, 446-712, Korea. doogie.chung@samsung.com., Cope L; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. Lcope1@jhmi.edu., Fackler MJ; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. facklma@jhmi.edu., Umbricht C; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. cumbrich@jhmi.edu., Sukumar S; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. saras@jhmi.edu., Seth P; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. pseth@bidmc.harvard.edu., Sukhatme VP; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. vsukhatm@bidmc.harvard.edu., Jakkula LR; Department of Cancer & DNA Damage Responses, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA. lrjk@hotmail.com., Lu Y; Department of Systems Biology, MD Anderson Cancer Center, Houston, TX, 77030, USA. yilinglu@mdanderson.org., Mills GB; Department of Systems Biology, MD Anderson Cancer Center, Houston, TX, 77030, USA. gmills@mdanderson.org., Cho RJ; Department of Dermatology, University of California, San Francisco, CA, 94115, USA. choR@derm.ucsf.edu., Collisson EA; Department of Cancer & DNA Damage Responses, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA. Eric.Collisson@ucsf.edu.; Laboratory Medicine, University of California San Francisco, San Francisco, CA, 94115, USA. Eric.Collisson@ucsf.edu., Van't Veer LJ; Laboratory Medicine, University of California San Francisco, San Francisco, CA, 94115, USA. VantveerL@cc.ucsf.edu., Spellman PT; Department of Cancer & DNA Damage Responses, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA. spellmap@ohsu.edu.; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR, 97239, USA. spellmap@ohsu.edu., Gray JW; Department of Cancer & DNA Damage Responses, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA. grayjo@ohsu.edu.; Department of Biomedical Engineering, Center for Spatial Systems Biomedicine, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, 97239, USA. grayjo@ohsu.edu.

Publikováno v: Genome biology [Genome Biol] 2015 May 12; Vol. 16, pp. 95. Date of Electronic Publication: 2015 May 12.

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

Autor: Daemen A; Laboratory Medicine, University of California San Francisco, 2340 Sutter Street Box 0808, San Francisco, CA 94115, USA. anneleen.daemen@gmail.com, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Spellman PT, Gray JW, van't Veer LJ

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2012 Sep; Vol. 135 (2), pp. 505-17. Date of Electronic Publication: 2012 Aug 09.